Eisai Clinical Trials

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer’s Disease

E2020-G000-326

Study Overview

E2020
donepezil
NCT00478205
Jun 2007 - Jun 2009
Alzheimer's disease
The primary objective of this study was to compare the efficacy of donepezil sustained release (SR) 23 mg with donepezil immediate release (IR) 10 mg in the treatment of patients with moderate to severe Alzheimer's disease.

  • Males and females (aged 45 to 90 years)

  • Completed

  • Phase 3

  • United States

Results

CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, double-blind study. Clin Ther. 2010;32:1234-51.

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR